Shen Ying-Hao, Huang Cheng, Zhu Xiao-Dong, Xu Ming-Hao, Chen Zhao-Shuo, Tan Chang-Jun, Zhou Jian, Fan Jia, Sun Hui-Chuan
From the Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Hepatobiliary Pancreatic Surgery, Fujian Medical University Cancer Hospital, Fuzhou, China.
Ann Surg Open. 2022 May 2;3(2):e163. doi: 10.1097/AS9.0000000000000163. eCollection 2022 Jun.
To determine the safety of hepatectomy after combined lenvatinib and anti-PD-1 preoperative systemic therapy (PST) in patients with marginally resectable hepatocellular carcinoma (HCC).
PST followed by hepatectomy (PSTH) is an emerging treatment for HCC. However, the impact of PST with lenvatinib plus anti-PD-1 antibodies on surgical safety is unknown.
Medical records from consecutive patients with marginally resectable advanced HCC who underwent hepatectomy after PST with lenvatinib and anti-PD-1 antibodies between January 2018 and August 2021 were retrieved from a prospectively designed database. Propensity score matching (1:2) was performed with a further 2318 HCC patients who underwent upfront hepatectomy (UH) without initial antitumor treatment during the same period.
In total, 49 and 98 matched patients were included in the PSTH and UH groups, respectively. Compared to the UH group, individuals in the PSTH group experienced more intraoperative blood loss, blood transfusions, and longer postoperative hospital stays. Moreover, posthepatectomy liver failure was more common in the PSTH group, who also had worse albumin-bilirubin (ALBI) scores on postoperative days 1-7. A significantly greater amount of drainage was also required in the PSTH group. However, the 30-day morbidity and 90-day mortality were similar among the two groups. Additionally, the duration of surgery, use of hepatic inflow occlusion during surgery, and the levels of postoperative inflammation-based markers were not statistically different between the two groups.
Despite more intraoperative and postoperative adverse events, PSTH had comparable 30-day morbidity and 90-day mortality as UH. Thus, PSTH appears to be a viable treatment option for marginally resectable HCC patients with careful preoperative evaluation.
确定在边缘可切除的肝细胞癌(HCC)患者中,乐伐替尼与抗程序性死亡蛋白1(PD-1)术前全身治疗(PST)联合应用后进行肝切除术的安全性。
PST后行肝切除术(PSTH)是一种新兴的HCC治疗方法。然而,乐伐替尼联合抗PD-1抗体的PST对手术安全性的影响尚不清楚。
从一个前瞻性设计的数据库中检索2018年1月至2021年8月期间接受乐伐替尼和抗PD-1抗体PST后行肝切除术的连续边缘可切除晚期HCC患者的病历。对另外2318例同期接受 upfront肝切除术(UH)且未进行初始抗肿瘤治疗的HCC患者进行倾向评分匹配(1:2)。
PSTH组和UH组分别纳入49例和98例匹配患者。与UH组相比,PSTH组患者术中失血更多、输血更多,术后住院时间更长。此外,肝切除术后肝衰竭在PSTH组更常见,且术后1-7天白蛋白-胆红素(ALBI)评分更差。PSTH组的引流量也明显更多。然而,两组的30天发病率和90天死亡率相似。此外,两组之间的手术时间、手术中肝血流阻断的使用情况以及术后炎症指标水平无统计学差异。
尽管有更多的术中和术后不良事件,但PSTH的30天发病率和90天死亡率与UH相当。因此,对于边缘可切除的HCC患者,经过仔细的术前评估,PSTH似乎是一种可行的治疗选择。